Epidemiological and Clinical Baseline Characteristics as Predictive Biomarkers of Response to Anti-VEGF Treatment in Patients with Neovascular AMD

Abstract EN

Purpose.

To review the current literature investigating patient response to antivascular endothelial growth factor-A (VEGF) therapy in the treatment of neovascular age-related macular degeneration (nAMD) and to identify baseline characteristics that might predict response.

Method.

A literature search of the PubMed database was performed, using the keywords: AMD, anti-VEGF, biomarker, optical coherence tomography, treatment outcome, and predictor.

The search was limited to articles published from 2006 to date.

Exclusion criteria included phase 1 trials, case reports, studies focusing on indications other than nAMD, and oncology.

Results.

A total of 1467 articles were identified, of which 845 were excluded.

Of the 622 remaining references, 47 met all the search criteria and were included in this review.

Conclusion.

Several baseline characteristics correlated with anti-VEGF treatment response, including best-corrected visual acuity, age, lesion size, and retinal thickness.

The majority of factors were associated with disease duration, suggesting that longer disease duration before treatment results in worse treatment outcomes.

This highlights the need for early treatment for patients with nAMD to gain optimal treatment outcomes.

Many of the identified baseline characteristics are interconnected and cannot be evaluated in isolation; therefore multivariate analyses will be required to determine any specific relationship with treatment response.